Biomarkers of treatment outcome in schizophrenia: Defining a benchmark for clinical significance

Stephen Z. Levine; Jonathan Rabinowitz; Rudolf Uher; Shitij Kapur

doi:10.1016/j.euroneuro.2015.06.008

Biomarkers of treatment outcome in schizophrenia: Defining a benchmark for clinical significance

Stephen Z. Levine, Jonathan Rabinowitz, Rudolf Uher, Shitij Kapur

Institutional Research Division

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

Original language	English
Pages (from-to)	1578-1585
Number of pages	8
Journal	European Neuropsychopharmacology
Volume	25
Issue number	10
DOIs	https://doi.org/10.1016/j.euroneuro.2015.06.008
Publication status	Published - Oct 2015

ASJC Scopus Subject Areas

Pharmacology
Neurology
Clinical Neurology
Psychiatry and Mental health
Biological Psychiatry
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.euroneuro.2015.06.008

Cite this

@article{a2af04b48844490fa98af55310f0037e,

title = "Biomarkers of treatment outcome in schizophrenia: Defining a benchmark for clinical significance",

author = "Levine, {Stephen Z.} and Jonathan Rabinowitz and Rudolf Uher and Shitij Kapur",

note = "Funding Information: Dr. Uher is supported by the Canada Research Chairs program, the Canadian Institutes of Health Research and the Nova Scotia Health Research Foundation. Dr. Levine has received research support, and/or consultancy fees and/or travel support from Shire, F. Hoffmann-LaRoche, and Eli Lilly. Dr. Rabinowitz has served as a consultant to Janssen (J&J), Eli Lilly, Pfizer, BiolineRx, Roche and Amgen, and is on scientific advisory board at MedAvante. Dr. Kapur has received recent grant support from Lundbeck and Roche and has served as a one-off consultant and/or speaker for Otsuka and Takeda and served on the Scientific Advisory Boards for Acadia, Lundbeck and Roche Funding Information: Dr. Kapur's involvement is supported by an MRC UK Award, STRATA and by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King{\textquoteright}s College London . Publisher Copyright: {\textcopyright} 2015 Elsevier B.V. and ECNP.",

year = "2015",

month = oct,

doi = "10.1016/j.euroneuro.2015.06.008",

language = "English",

volume = "25",

pages = "1578--1585",

journal = "European Neuropsychopharmacology",

issn = "0924-977X",

publisher = "Elsevier",

number = "10",

}

TY - JOUR

T1 - Biomarkers of treatment outcome in schizophrenia

T2 - Defining a benchmark for clinical significance

AU - Levine, Stephen Z.

AU - Rabinowitz, Jonathan

AU - Uher, Rudolf

AU - Kapur, Shitij

N1 - Funding Information: Dr. Uher is supported by the Canada Research Chairs program, the Canadian Institutes of Health Research and the Nova Scotia Health Research Foundation. Dr. Levine has received research support, and/or consultancy fees and/or travel support from Shire, F. Hoffmann-LaRoche, and Eli Lilly. Dr. Rabinowitz has served as a consultant to Janssen (J&J), Eli Lilly, Pfizer, BiolineRx, Roche and Amgen, and is on scientific advisory board at MedAvante. Dr. Kapur has received recent grant support from Lundbeck and Roche and has served as a one-off consultant and/or speaker for Otsuka and Takeda and served on the Scientific Advisory Boards for Acadia, Lundbeck and Roche Funding Information: Dr. Kapur's involvement is supported by an MRC UK Award, STRATA and by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London . Publisher Copyright: © 2015 Elsevier B.V. and ECNP.

PY - 2015/10

Y1 - 2015/10

UR - http://www.scopus.com/inward/record.url?scp=84943363681&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943363681&partnerID=8YFLogxK

U2 - 10.1016/j.euroneuro.2015.06.008

DO - 10.1016/j.euroneuro.2015.06.008

M3 - Article

C2 - 26145487

AN - SCOPUS:84943363681

SN - 0924-977X

VL - 25

SP - 1578

EP - 1585

JO - European Neuropsychopharmacology

JF - European Neuropsychopharmacology

IS - 10

ER -

Biomarkers of treatment outcome in schizophrenia: Defining a benchmark for clinical significance

ASJC Scopus Subject Areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this